Ligand-Based Virtual Screening

The LBVS method is given a group of ligands with diverse structures that bind to the receptor, and a receptor model can be built by using the collective information contained in the group of ligands. These are called pharmacophore models. One popular method of ligand-based virtual screening is based on searching for molecules with a shape similar to known active substances, because such molecules will fit the target's binding site and therefore may bind to the target. LBVS has significant advantages over other virtual screening methods because it does not involve macromolecular calculations and does not require prior knowledge of active ligands. It was selected as one of the most popular drug discovery and lead optimization methods, especially when there is no three-dimensional structure of potential drug targets.

Figure 1. Virtual Screening. (Maia E H B,et al.2020)

Figure 1. Virtual Screening. (Maia E H B,et al.2020)

Overall solutions

Ligand-based methods are based on the principle of structure determining properties. Such methods include:
1) Pharmacophore modeling is to study the pharmacophore of a series of known active compounds, and summarize some groups that play a key role in the activity of the compound through conformational analysis, molecular superposition and other methods information;
2) Quantitative structure activity relationship (QSAR) is a method of quantitatively studying the interaction of small organic molecules and biological macromolecules with the help of the physical and chemical property parameters or structural parameters of molecules. Methods of absorption, distribution, metabolism, excretion and other physiological properties in the organism;
3) The structural similarity method (SSIM) uses various descriptors or fingerprints to perform similarity matching to determine whether the compound has similar activity or therapeutic mechanism.

AI-based approaches

Machine Learning (ML) belongs to the sub-field of artificial intelligence. It is the study of the process and practicality of machines that can perform intelligent tasks proficiently without explicit programming for these tasks. Artificial intelligence can play a key role in virtual screening, especially artificial neural networks, such as deep neural networks or recurrent networks, driving the development of this field. Recurrent Neural Networks (RNNs) have been successfully applied to virtual screening. Initially, they were established in the field of natural language processing. RNN takes order information as input. Since SMILES strings encode chemical structures in letter sequences, RNNs have been used to generate chemical structures. In order to train the neural network SMILES string grammar, RNNs received training on a large set of compounds extracted from the existing compound collection, such as ChEMBL or commercial compounds. Studies have shown that RNNs can generate a large number of valid SMILES strings. The same method has also been successfully used to generate new peptide structures. Reinforcement learning models are successfully applied to bias the generated compounds toward the desired properties.

Services items

Project name Ligand-Based Virtual Screening (LBVS)
Advantages
  • Rich experience in the development of pharmacophore and QSAR models involved in LBVS.
  • Our drug discovery scientists have the ability to prioritize the most promising hits.
  • Considering cost-effectiveness.
Services

MedAI can provide you with the following service but not limited to:

  • Quantitative structure-activity relationship (QSAR) modeling
  • Pharmacophore searching
  • Similarity searching
  • AI-based virtual screening
Cycle Depends on the time you need to simulate and the time required for the system to reach equilibrium.
Product delivery mode The simulation results provide you with the raw data and analysis results of molecular dynamics.
Price Inquiry

Applications

  • Pharmaceutical-related research groups: engaged in pharmaceutical-related research groups such as drug design, drug synthesis, and activity screening;
  • Drug Screening and Evaluation Center: National and local drug screening centers, pharmacological evaluation centers, and systematic management of compound libraries and pharmacological screening models in the center;
  • Pharmaceutical companies: Fully manage the internal compound library and its screening.

MedAI continues to improve its computing power to support the screening and evaluation of more compounds. We improve the screening process by investing in high-performance computing infrastructure. For each virtual drug screening project, our scientists will discuss with the client and then design an appropriate and cost-effective screening solution. If you have any needs in this regard, please feel free to contact us.

References

  • Maia E H B , Letícia Cristina Assis, Oliveira T A D , et al. Structure-Based Virtual Screening: From Classical to Artificial Intelligence. Frontiers in Chemistry, 2020, 8:343.

Services

Online Inquiry

Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to inquiry@protheragen.com for inquiries.

Verification code

Copyright © 2021 Protheragen Inc. All Rights Reserved.